Premium
Pharmacoeconomic studies of antidepressants: Focus on venlafaxine
Author(s) -
Woods Scott W.
Publication year - 2000
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/1520-6394(2000)12:1+<102::aid-da15>3.0.co;2-u
Subject(s) - venlafaxine , medicine , offset (computer science) , retrospective cohort study , intensive care medicine , psychiatry , computer science , antidepressant , anxiety , programming language
Newer antidepressants are more expensive in terms of acquisition costs than older drugs. However, cost effectiveness simulations and retrospective analyses of administrative databases of newer antidepressants, including venlafaxine, suggest that the higher acquisition costs may be offset or more than offset by savings of other treatment costs. Because simulations and retrospective studies are vulnerable to multiple methodologic uncertainties, large scale randomized “real‐world” cost effectiveness experiments are needed. If venlafaxine in actual practice is more effective or has a more rapid onset of action than SSRIs as suggested by efficacy studies and existing meta‐analyses, these effects could translate into pharmacoeconomic advantages. Depression and Anxiety, Volume 12, Supplement 1:102–109, 2000. © 2000 Wiley‐Liss, Inc.